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Downregulation of p53 by MDM2-mediated proteasomal
degradation makes cells resistant to apoptosis. The
MDM2–p53 interaction is well characterized, but the me-
chanisms that regulate the interaction are not well under-
stood. Here, we show that PA28c, a proteasome activator
that inhibits apoptosis and promotes cell cycle progression
through unknown mechanisms, exerts an effect as a
cofactor in the MDM2–p53 interaction. The polymer form
of PA28c interacts with both MDM2 and p53 proteins
and facilitates their physical interaction. This promotes
ubiquitination- and MDM2-dependent proteasomal degra-
dation of p53, limiting its accumulation and resulting in
inhibited apoptosis after DNA damage. Elimination of
endogenous PA28c in human cancer cells abrogates
MDM2-mediated p53 degradation, increases the activity
of p53, and enhances apoptosis. These ﬁndings reveal the
mechanism by which PA28c affects apoptosis and prolif-
eration. Manipulation of the level of PA28c, an approach
that would regulate the cellular content of p53, may
improve the efﬁcacy of current cancer therapies.
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Introduction
Tumor suppressor p53 is involved in controlling cell growth
and differentiation and in the maintenance of genomic in-
tegrity, with high levels of p53 activity inducing apoptosis,
cell cycle arrest, or senescence (Lane, 1992). The regulation
of p53 protein expression and activity in cells is of particular
interest in the ﬁeld of cancer research, both for the develop-
ment of more effective therapeutic strategies and for ongoing
efforts to gain a better understanding of tumorigenesis.
The level of p53 protein is elevated upon exposure of cells
to stress, such as DNA damage, hypoxia, nutrient depriva-
tion, or oncogene activation (Levine, 1997). In unstressed
cells, the level of p53 (hence its activity) is largely controlled
by MDM2, an oncoprotein containing an ubiquitin E3
ligase (Haupt et al, 1997; Brooks and Gu, 2006). MDM2
promotes the polyubiquitination of p53, which is an essential
step in its degradation (Haupt et al, 1997; Brooks and Gu,
2006).
Although it is known that the MDM2–p53 interaction is
controlled by an autoregulatory loop (Haupt et al, 1997;
Brooks and Gu, 2003, 2006; Zhang et al, 2005) and that the
MDM2-mediated degradation of p53 is dependent upon the
cellular level of MDM2 (Li et al, 2003), the mechanisms
regulating this interaction appear to be complex and are
poorly understood. It was suggested that a cofactor may be
required for MDM2-mediated p53 degradation because low
levels of MDM2 fail to catalyse polyubiquitination of p53
(Li et al, 2003).
PA28g (REGg, PSME3, Ki antigen) belongs to a family of
activators of the 20S proteasome (Rechsteiner and Hill, 2005).
Unlike its family members, PA28a and PA28b, PA28g is
localized within the nucleus and forms a homoheptamer
(rather than a heterocomplex). PA28g has been implicated
in the regulation of cell cycle progression and apoptosis, and
embryonic ﬁbroblasts of PA28g nullizygous mice demon-
strate spontaneous apoptosis and G1 arrest (Rechsteiner
and Hill, 2005). These mice also have a reduced adult body
mass and show growth retardation (Rechsteiner and Hill,
2005). The mechanism by which PA28g exerts these effects
has not been elucidated. These ﬁndings prompted us to
explore the possibility that PA28g may regulate p53. Here,
we report that PA28g has an integral function in the degrada-
tion of p53, and that it does so by acting as an essential
cofactor that promotes the binding of MDM2 and p53.
Results
PA28c negatively regulates p53
Overexpression of PA28g, but not PA28b, reduced the level of
p53 protein and its transactivational activity (measured by
p21
Waf1 protein) in LNCaP, MCF-7, and U2OS cells (p53 wild
type), but not in PC3 cells (p53 null) (Figure 1A). Knockdown
of endogenous PA28g using a small interfering RNA (siRNA)
pool (Dharmacon) increased the levels of endogenous p53
and p21
Waf1 in LNCaP, HCT116, A549, MCF-7, and MCF10A
(a normal breast epithelial line) cells, but not PC3 cells
(Figures 1B–D and Supplementary Figure S1). Although
PA28g levels were decreased in all eight cell lines treated
with PA28g siRNA (Figures 1B and C and Supplementary
Figures S1 and S2); levels of the homologue PA28b showed
little or no change, indicating that the off-target effects of the
siRNA pool were minimal (Figure 1B and Supplementary
Figure S1).
Conﬁrming that induction of p21
Waf1 after PA28g knock-
down is p53 dependent, when MCF10A cells were transfected
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852with an siRNA pool targeting PA28g, p53, or both, the
induction of p21
Waf1 was largely inhibited when p53 was
knocked down (Figure 1C). Furthermore, an increase in
p21
Waf1 mRNA after PA28g knockdown by siRNA was
observed in HCT116 cells, but not in p53
 /  HCT116
cells (Figure 1D). At the post-translational level, the
extent of the induction of p21
Waf1 in p53
 /  HCT116
cells was much less than in HCT116 cells (Figure 1D).
These results suggest that the induction of p21
Waf1 after
PA28g knockdown occurs largely through p53. However,
modulation of p21
Waf1 directly by PA28g at the post-transla-
tional level is also possible.
Two individual PA28g siRNA duplexes and one control
siRNA duplex were randomly selected from the previous
siRNA pools to conﬁrm that PA28g negatively regulates p53.
Each of the PA28g siRNA duplexes was capable of down-
regulating endogenous PA28g, resulting in dose-dependent
accumulation of p53 in HCT116 cells (Figure 1E, left panel).
In contrast, randomly selected PA28b siRNA duplexes from
the PA28b siRNA pool (Dharmacon) did not affect the level of
p53, although endogenous PA28b was knocked down
(Figure 1E, right panel). Additionally, p53 was elevated in
PA28g
 /  mouse embryonic ﬁbroblasts (MEFs) (with low
passage numbers) compared with wild-type MEF (Figure 1F).
This elevation in p53 was decreased by overexpressed PA28g
(Figure 1G).
Several p53 targets (including p21
Waf1, Puma, and
14-3-3s), and p53 itself, were downregulated by ectopic
PA28g in wild-type MEF cells (Figure 1H). In HCT116 cells,
knockdown of PA28g led to induction of p53 at the protein
level and increases in p21
Waf1, Puma, and 14-3-3s at both
the mRNA and protein levels (Figure 1I). Similar results were
obtained in MCF-7 cells (Supplementary Figure S3).
Overexpression of PA28g, but not PA28b, in MCF-7 cells co-
transfected with a luciferase reporter under the control of the
p21
Waf1 promoter, inhibited p53-dependent transcriptional
activity (Figure 1J, left panel). Co-transfection with p53
reversed the PA28g-mediated inhibition of p53-dependent
transcriptional activity (Figure 1J, right panel).
PA28c promotes ubiquitination-dependent proteasomal
degradation of p53
We hypothesized that PA28g downregulates p53 by promot-
ing its degradation. Conﬁrming this hypothesis, overexpres-
sion of PA28g increased degradation of endogenous p53
protein in LNCaP cells (Figure 2A), and increased the amount
of proteasome-bound p53 in PA28g-overexpressing U2OS
cells (Figure 2B). In MCF-7 cells, overexpression of PA28g
enhanced the ubiquitination of p53 (Figure 2C).
The stability of p53 in ts20b cells, which express a
temperature-sensitive E1 ubiquitin-activating enzyme, was
examined to determine whether the promotion of p53 degra-
dation by PA28g is ubiquitination dependent. PA28g lost
its capacity to promote p53 degradation when the ts20b
cells were cultured at 391C. However, its promotion of
ubiquitin-independent proteasomal degradation of p21
Waf1
was retained (Figure 2D).
To exclude the possibility that PA28g may have a post-
ubiquitination effect in promoting degradation of ubiquiti-
nated p53 through the proteasome, ubiquitinated p53 was
incubated with either 20S or 26S proteasome in the presence
of PA28g. The 20S proteasome alone did not degrade ubiqui-
tinated p53, and PA28g did not activate the 20S proteasome
to degrade ubiquitinated p53 (Figure 2E, upper panel).
Although the 26S proteasome degraded ubiquitinated p53,
PA28g did not enhance this activity (Figure 2E, lower panel).
In contrast, PA28g enhanced the degradation of p21
Waf1 by
the 20S proteasome (Figure 2F).
PA28c is a cofactor for MDM2-mediated p53 degradation
The PA28g protein does not have a motif characteristic of an
ubiquitin E3 ligase, suggesting that PA28g may promote the
ubiquitinating activity of another molecule. To test this
hypothesis, we examined whether PA28g promotes MDM2-
mediated p53 ubiquitination and degradation. Co-transfec-
tion of low amounts of MDM2 and PA28g into MCF-7 cells
enhanced the downregulation of p53 (Figure 3A). Although
low amounts of PA28g or MDM2 transfected alone into
LNCaP cells (Figure 3B) or A549 cells (Figure 3C) minimally
induced p53 ubiquitination, co-transfection with both PA28g
and MDM2 enhanced its ubiquitination (Figures 3B and C).
The possibility that the enhanced ubiquitination was a result
of changes in the pool of cellular-free ubiquitin, E1 or E2 was
excluded using puriﬁed recombinant proteins in in vitro
ubiquitination assays. Incubation of a lower amount of
MDM2 protein with puriﬁed p53 protein, along with puriﬁed
E1, E2 and ubiquitin in vitro, resulted in minimal ubiquitina-
tion of the p53 protein (Figure 3D). When recombinant PA28g
was included in the reaction, the ubiquitination of p53 was
increased (Figure 3D).
Exposure to a high concentration of Nutlin-3 (10mM), a
known inhibitor of the MDM2–p53 interaction, 12 hours after
transfection of MCF-7 cells with PA28g reversed the effects of
PA28g on p53 (Figure 3E). Exposure of LNCaP cells to an anti-
MDM2 antisense oligonucleotide (AS) (Zhang et al, 2005),
but not its mismatch control (ASM), prevented the induction
of p53 degradation by PA28g (Figure 3F). Co-transfection of
U2OS cells with MDM2 ASM or AS and various amounts
of PA28g further indicated that the PA28g-mediated
reduction in the p53 level is dependent on the presence of
MDM2 (Figure 3G). When PA28g was knocked down in A549
cells by siRNA prior to transfection with MDM2, the down-
regulatory effect of MDM2 on p53 was not observed
(Figure 3H).
The kinetics of the changes in expression and transactiva-
tional activity of p53 after g-irradiation were compared in
A549 cells overexpressing either MDM2 or PA28g (Figure 3I).
Both MDM2 and PA28g limited the accumulation of p53
and the elevation of p53 activity (manifested by the level of
p21
Waf1) with similar kinetics after DNA damage (Figure 3I),
indicating that they work via the same pathway. When PA28g
was pre-knocked down by siRNA, neither a low concentra-
tion of Nutlin-3 (3mM) (Figure 3J) nor overexpressed p14
Arf
(Figure 3K) led to modulation of the level of p53. This
is likely due to the fact that the MDM2–p53 interaction
(the target of both Nutlin-3 and p14
Arf) is disrupted by the
absence of PA28g. Another cofactor for the MDM2–p53
interaction, Daxx, also lost its capacity to downregulate p53
in the absence of PA28g (Figure 3L). In contrast, YY1 retained
its capacity for downregulating p53 (Figure 3M), indicating
that the mechanism by which YY1 enhances the MDM2–p53
interaction is different from that of PA28g.
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MDM2–p53 interaction
The stability of MDM2 did not change in PC3 cells transfected
with either PA28g or the control vector (Supplementary
Figure S4), suggesting that it is unlikely that PA28g modulates
the level of p53 by inhibiting the capacity of MDM2 to
catalyse self-ubiquitination. As PC3 cells are p53 null,
changes in MDM2 are not a result of alterations in p53
induced by PA28g.
Direct physical interactions between endogenous PA28g
and p53 proteins, as well as between endogenous PA28g and
MDM2 proteins, were observed in MCF-7 cells (Figure 4A).
Conﬁrmation of these direct interactions was obtained by use
of pull-down assays (Figure 4B), and immunoprecipitation
p53
p21Waf1
Flag
β β-Actin
p53
p21Waf1
p21Waf1
β-Actin
pEF-PA28γ
-Flag
pEF-PA28γ
-Flag
pEF-PA28γ
-Flag
pEF-PA28γ
-Flag
p
c
D
N
A
3
p
c
D
N
A
3
-
P
A
2
8
β
-
F
l
a
g
p
E
F
p
c
D
N
A
3
p
c
D
N
A
3
-
P
A
2
8
β
-
F
l
a
g
p
E
F
p
c
D
N
A
3
p
c
D
N
A
3
-
P
A
2
8
β
-
F
l
a
g
p
E
F
p
c
D
N
A
3
p
c
D
N
A
3
-
P
A
2
8
β
-
F
l
a
g
p
E
F
siRNA
pool
LNCaP MCF-7 U2OS PC3
LNCaP HCT116 PC3
MCF10A HCT116
+ ++ +++ + +++ + +++
Control
+ +++
siRNA pool siRNA pool
C
o
n
t
r
o
l
P
A
2
8
γ
p
5
3
P
A
2
8
γ
+
p
5
3
C
o
n
t
r
o
l
P
A
2
8
γ
p53
PA28γ 
MEF
p53
p53 (short
exposure)
PA28γ 
PA28γ-Flag
MEF
PA28γ–/– PA28γ+/+
PA28γ–/– PA28γ+/+
(PA28γ+/+)
PA28γ-Flag – + – + siRNA
Duplex
0.1 nM 1 nM 10 nM
C
o
n
t
r
o
l
C
o
n
t
r
o
l
P
A
2
8
β
 
β
 
n
o
.
 
2
P
A
2
8
β
 
β
 
n
o
.
 
1
P
A
2
8
β
 
β
 
n
o
.
 
2
P
A
2
8
β
 
β
 
n
o
.
 
1
C
o
n
t
r
o
l
P
A
2
8
β
 
β
 
n
o
.
 
2
P
A
2
8
β
 
β
 
n
o
.
 
1
C
o
n
t
r
o
l
P
A
2
8
γ
 
γ
 
n
o
.
 
2
P
A
2
8
γ
 
γ
 
n
o
.
 
1
C
o
n
t
r
o
l
P
A
2
8
γ
 
γ
 
n
o
.
 
2
P
A
2
8
γ
 
γ
 
n
o
.
 
1
C
o
n
t
r
o
l
P
A
2
8
γ
 
γ
 
n
o
.
 
2
P
A
2
8
γ
 
γ
 
n
o
.
 
1
siRNA
Duplex
1 nM 10 nM 50 nM
p53
PA28β
–+
Puma
14-3-3σ
RLU (% control) RLU (% control)
0 40 80 120 0 100 200 300 400 500
p531.5 µg
p530.5 µg
p530 µg
MEF
1 2.98 0.69 1.16
1 4.1 0.33 0.72
1 3.5 0.56 0.54
siRNA
pool
C
o
n
t
r
o
l
P
A
2
8
γ
P
A
2
8
γ
C
o
n
t
r
o
l
p53
(longer exposure)
PA28γ
1 1.06 1.02 3.89
1 1.03 1.05 2.4
1 0.98 0.96 2.7
N
e
g
a
t
i
v
e
D
h
a
r
m
a
f
e
c
t
i
n
C
o
n
t
r
o
l
 
s
i
R
N
A
P
A
2
8
γ
 
s
i
R
N
A
PA28γ Control PA28γ
PA28γ p53
p21Waf1
p21Waf1
p21Waf1
β-Actin
p21Waf1
β-Actin
β-Actin
p53 p21Waf1
p21Waf1
Puma
Puma
14-3-3σ
14-3-3σ
p53
PA28γ-Flag
PA28γ
PA28β  β 4 µg
PA28γ  γ 4 µg
PA28γ  γ 2 µg
PA28γ  γ 1 µg
PA28γ  γ 0 µg
PA28β  β 0 µg
PA28γ  γ 0 µg
PA28β  β 0 µg
PA28γ  γ 1 µg
PA28γ  γ 2.5 µg
PA28β  β 2.5 µg PA28γ-Flag
β-Actin
β-Actin
β-Actin
β-Actin
β-Actin
β-Actin
β-Actin
β-Actin
PA28γ
PA28β
p53
β-Actin
PA28γ
Control PA28γ
PA28c modulates MDM2–p53 interaction
Z Zhang and R Zhang
The EMBO Journal VOL 27 | NO 6 | 2008 &2008 European Molecular Biology Organization 854with overexpressed PA28g-GFPand p53-HA (haemagglutinin)
(Figure 4C, upper panel) and PA28g-GFP and MDM2-T7
(Figure 4C, lower panel) in COS7 cells.
To determine if PA28g promotes the MDM2–p53 interac-
tion, lysates from U2OS cells overexpressing different
amounts of PA28g were immunoprecipitated with p53 anti-
body, and it was observed that the MDM2 level was higher in
the p53 immunoprecipitates from cells that were transfected
with PA28g (Figure 4D, left panel). Moreover, the amount of
MDM2 in p53 immunoprecipitates from A549 cells treated
with the PA28g siRNA pool was lower than that from cells
treated with the control siRNA pool (Figure 4D, right panel).
The amount of p53 bound to GST-MDM2 was also enhanced
by the addition of PA28g in an in vitro pull-down assay
(Figure 4E). Finally, the amount of MDM2 bound by p53 in
PA28g
 /  MEF cells was higher than in wild-type MEF cells
(Figure 4F).
To determine which form of PA28g (monomer/polymer)
mediates the MDM2–p53 interaction, gel ﬁltration chromato-
graphy was performed. The elution proﬁle of the lysates from
COS7 cells transfected with GFP-PA28g, p53-HA, and MDM2-
T7 showed a peak that was absent in the proﬁle from the cells
transfected with GFP, p53-HA, and MDM2-T7 (Figure 4G, left
panel). The molecular weight of this peak was estimated
to be 560kDa, corresponding to a complex of heptameric
GFP–PA28g–MDM2–p53 (the molecular weight of GFP-PA28g
is 60kDa) (Figure 4G, left panel). The eluted fractions were
resolved on 10% SDS–PAGE and immunoblotted using T7,
HA, and GFP antibodies (Figure 4G, right panel).
In GFP-PA28g-transfected cells, GFP-PA28g, MDM2-T7,
and p53-HA appeared simultaneously in the fractions with
molecular weights from about 440kDa to more than 669kDa
(Figure 4G, right panel). Moreover, GFP-PA28g barely
appeared in the fractions with molecular weights less than
232kDa, suggesting that GFP-PA28g primarily exists in the
polymer form in cells. In GFP-transfected cells, p53-HA and
MDM2-T7 appeared simultaneously only in the fractions with
lower molecular weight, about 400–440kDa (Figure 4G,
right panel). To assess the capacity of GFP-PA28g to form
polymers, an in vitro approach employing glutaraldehyde
(to covalently crosslink any polymers that form) was
performed (Supplementary Figure S5). GFP-PA28g and three
mutants, P245Y, G150S, and N151Y (incapable of activating
the proteasome), were all capable of forming polymers
(Supplementary Figure S5).
PA28c speciﬁcally downregulates p53
To conﬁrm that PA28g does not regulate p53 directly through
its proteasome-binding or -activating functions, we tested the
activity of three mutants of PA28g; P245Y (incapable of
binding the 20S proteasome; Zhang et al, 1998b), and
G150S and N151Y (unable to activate, but still able to bind
the proteasome; Zhang et al, 1998b). Similar half-lifes for
endogenous p53 protein were found in cells that were trans-
fected with PA28g and cells transfected with any of the three
mutants (Figure 5A). Notably, the homologue-speciﬁc ‘insert
region’ of PA28g (amino acids 71–103) that differentiates
it from other PA28 family members (Zhang et al, 1998b)
was demonstrated to be essential for the promotion of poly-
ubiquitination and degradation of p53 (Figures 5A–C).
We have further deﬁned the regions that are essential for
the binding of PA28g to MDM2 and p53, both of which are
within the insert region. A PA28g mutant without amino
acids 76–103 did not bind to MDM2, but PA28g 66–161,
PA28g 86–255, and PA28g 96–255 all bound MDM2
(Figures 5D, F and Supplementary Figure S6A), indicating
that amino acids 96–103 are essential for PA28g binding to
MDM2 (Figures 5D, F and Supplementary Figure S6A). We
also determined that amino acids 86–96 are required for
binding p53 (Figures 5E, F and Supplementary Figure S6B).
Figure 1 PA28g regulates the expression and transactivational activity of p53. (A) p53 is downregulated by overexpressed PA28g, but not by
PA28b. LNCaP, MCF-7, U2OS, and PC3 cells were transfected to overexpress PA28g (0, 1.5, 3 and 5mg), or PA28b (5mg), or their corresponding
control vectors. After 24h, whole cell lysates were collected for detection of target proteins by immunoblotting. The p53 protein level is
elevated after PA28g knockdown in human cancer cells (B) and normal cells (C). (B) LNCaP, HCT116, and PC3 cells were transfected with a
control or a PA28g siRNA pool (1.25nM for each duplex) and incubated for 24h, target proteins were detected by immunoblotting. (C) Human
normal breast epithelial MCF10A cells were incubated with an siRNA pool targeting PA28g or p53, or a control siRNA pool (1.25nM for each
duplex) for 24h. Target proteins were detected by immunoblotting. The numbers under the p21
Waf1 band indicate expression as a percentage of
the control siRNA, normalized to the corresponding b-actin level. (D) HCT116 or HCT116 p53
 /  cells were treated with siRNA pools (1.25nM
for each duplex). Cells were harvested 24h later for extraction of either protein or total RNA. The levels of target proteins including p53 and
p21
Waf1 were examined by immunoblotting. The numbers under the p21
Waf1 band indicate expression as a percentage of the control siRNA,
normalized to the corresponding b-actin level. The mRNA level of p21
Waf1 was analysed by RT–PCR in which p21
Waf1 mRNAwas co-ampliﬁed
with b-actin mRNA in the same reaction. The number under each band is expressed as a percentage of control siRNA, normalized by the
corresponding co-ampliﬁed b-actin mRNA level. (E) siRNAduplexes targeting PA28g, but not those targeting PA28b, elevate the cellular level of
p53. HCT116 cells were treated with two siRNA duplexes targeting PA28g, or PA28b, or with a control siRNA duplex, at various concentrations
for 48h before whole cell lysates were collected for detection of target proteins. (F, G) Knockdown of PA28g in transgenic mice results in an
increase in p53. (F) Target proteins in low passage mouse embryonic ﬁbroblasts (MEFs) isolated from wild-type or PA28g knockdown mice
were examined by immunoblotting. (G) PA28g
þ/þ and PA28g
 /  MEFs were transfected with a plasmid expressing PA28g (3mg), 24h later,
whole cell lysates were collected for detection of target proteins. (H–J) PA28g negatively regulates p53 transactivational activity. (H) PA28g
þ/þ
MEFs were transfected with a plasmid expressing PA28g (3mg), 24h later, cell lysates were collected for detection of target proteins. (I) HCT116
cells were treated with control siRNA duplex, PA28g siRNA duplex, or transfection reagent (Dharmafectin), or left untreated (negative). Cells
were harvested 24h later for extraction of either protein or total RNA. The levels of target proteins including p53 and p21
Waf1 were examined by
immunoblotting. The mRNA expression of p21
Waf1, Puma, and 14-3-3s was analysed by RT–PCR in which p21
Waf1 mRNA, Puma mRNA, or
14-3-3s mRNA was co-ampliﬁed with b-actin mRNA in the same reaction. The number under each band is expressed as a percentage of the
negative control, normalized to the corresponding co-ampliﬁed b-actin mRNA level. (J) MCF-7 cells were co-transfected with various amounts
of PA28g or PA28b with p21
Waf1 luciferase reporter (1.5mg) and Renilla luciferase reporter (0.3mg) (internal control; Promega). After 28h, the
luciferase activity of the p21
Waf1 promoter reporter was determined using the Dual-Luciferase Reporter Assay System (Promega) according to
the manufacturer’s protocol. The p21
Waf1 reporter activity was normalized to the corresponding Renilla luciferase reporter activity (left panel).
In a separate experiment, MCF-7 cells were co-transfected with PA28g or PA28b with p53, p21
Waf1 luciferase reporter, and Renilla luciferase
reporter. After 28h, the luciferase assay was performed as above (right panel). The relative luciferase units (RLUs) represent the means7s.d. of
two independent samples.
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transfected with PA28g (4mg) or corresponding empty vector for 24h, followed by exposure to cycloheximide (CHX) (10mg/ml) for different times.
Target proteins in whole cell lysates were detected by immunoblotting. The intensity of the p53 protein band was analysed by densitometry (Bio-Rad
Model GS-670 Imaging Densitometer; Bio-Rad). The relative densitometry data at each time point are expressed as a percentage of the density at time 0,
after normalization to the corresponding b-actin level. The average relative densitometry data of three independent experiments are shown in the right
panel. *Po0.05. (B)P A 2 8 g induces proteasome binding of p53. U2OS cells with PA28g (0 or 4mg) were evaluated for proteasome-bound p53
by immunoprecipitation with an antibody to the proteasome a/b subunits followed by detection of p53 by immunoblotting with p53 antibody
DO-1. Proteasomal ATPase subunit Rpt1/S7 was included to verify equal protein loading. (C) p53 ubiquitination is enhanced in cells with PA28g
overexpression. HA-Ub (3mg) and PA28g (3mg) were overexpressed in MCF-7 cells followed by exposure to MG132. Ubiquitinated p53 was detected by
direct immunoblotting with the DO-1 antibody. (D) The promotion of p53 degradation by PA28g depends on the integrity of the ubiquitin–proteasome
pathway. ts20b cells were incubated at 32 or 391C for 12h before being transfected with plasmids to overexpress PA28g (3.5mg) or control vector. The
stability of p53 and p21
Waf1 proteins was determined 24h later as described in (A). (E)P A 2 8 g does not promote proteasomal degradation of
ubiquitinated p53. Ubiquitinated p53 was incubated with 20S or 26S proteasome in the presence or absence of PA28g at 371Cf o r5h .T h er e a c t i o nw a s
terminated by boiling with SDS sample buffer for 5min. Ubiquitinated p53 was detected by immunoblotting. (F)P A 2 8 g promotes p21
Waf1 degradation
by the 20S proteasome. p21
Waf1 was incubated with 20S proteasome in the presence or absence of PA28g at 371C for 45min. The reaction was
terminated by boiling with SDS sample buffer for 5min. p21
Waf1 was detected by immunoblotting.
Figure 3 PA28g functions as a critical cofactor for MDM2-mediated p53 degradation. (A)M D M 2a n dP A 2 8 g synergistically decrease p53 protein. MCF-7
cells were transfected with low amounts of MDM2 (0, 1, or 1.5mg )i nt h ep r e s e n c eo ra b s e n c eo fP A 2 8 g (0 or 1.5mg) for 24h. Endogenous p53 protein
expression in whole cell lysates was examined by immunoblotting. (B, C)M D M 2a n dP A 2 8 g synergistically induce p53 ubiquitination in cells. (B) Different
combinations of MDM2 (0 or 2mg), Ub-HA (0 or 2mg), and/or PA28g (0 or 2mg) were expressed in LNCaP cells. Ubiquitinated p53 was immunoprecipitated
using p53 antibody DO-1, and the precipitates were immunoblotted using antibodies against HA and ubiquitin. *Ubiquitinated p53. (C) A549 cells were
transfected with MDM2, Ub-HA, and PA28g as described in (B). 24h later, cells were incubated with MG132 (15mM) for 4h. Cell lysates were
immunoprecipitated by p53 antibody FL393, and the precipitates were immunoblotted with an antibody against the polyubiquitin chain, FK1. (D) In vitro
ubiquitination of p53 by MDM2 is enhanced by PA28g. His-p53 (6ng) was incubated with His-MDM2 (3ng) and GST-PA28g(30ng) for 3h in the presence of
E1 (10ng), E2 (40ng), and ubiquitin (5mg). Ubiquitinated p53 was detected by immunoblotting with the p53 antibody, DO-1. (E) The downregulation of p53
by PA28g is reversed by Nutlin-3. MCF-7 cells were transfected with the PA28g plasmid (3.5mg) or control vector (3.5mg), and incubated for 24h. At 12h
before the termination of the incubation, cells were exposed to 10mM Nutlin-3 or the solvent, DMSO. Target proteins in whole cell lysates were detected by
immunoblotting. (F, G)P A 2 8 g loses the capacity to induce p53 degradation when MDM2 is knocked down by MDM2 antisense oligonucleotides. (F) LNCaP
cells were co-transfected with PA28g (4mg) or control vector (4mg) with an MDM2 antisense oligonucleotide (AS) (150nM) or a mismatch control
oligonucleotide (ASM) (150nM). After 24h, p53 stability was determined as described above. (G) U2OS cells were co-transfected with MDM2 AS (150nM)
or ASM (150nM) with various amounts of PA28g ( 0 ,1 . 5 ,3 ,o r5mg). The p53 protein level in cell lysates was determined by immunoblotting. (H)P A 2 8 g is
required for MDM2-mediated p53 degradation. A549 cells were transiently transfected with a control siRNA pool (1.25nM for each duplex) or a PA28gsiRNA
pool (1.25nM for each duplex) to knockdown endogenous PA28g. Cells were transfected with a plasmid to overexpress MDM2 (3mg) or a control vector
(3mg) 24h later. After an additional 24h, target proteins were detected by immunoblotting. (I)P A 2 8 g and MDM2 exhibit similar kinetics in limiting the
accumulation of p53 induced by g-irradiation. A549 cells were transfected with plasmids overexpressing MDM2 or PA28g (3.5mg for each). 24h later, cells
were exposed to 8Gy g-irradiation, and whole cell lysates were collected at different time points after irradiation for detection of target proteins. (J)T h ee f f e c t
of Nutlin-3 on p53 requires PA28g. A549 cells pretreated with the PA28g siRNA pool (1.25nM for each duplex for 12h) were incubated with 3mM Nutlin-3
for another 12h. Target proteins were examined by immunoblotting. (K)p 1 4
Arf cannot induce accumulation of p53 when PA28g is knocked down. HCT116
cells pre-incubated with the PA28g siRNA pool or control siRNA pool (1.25nM for each duplex) for 24h were transfected with plasmids overexpressing
p14
Arf (3mg) or a control vector (3mg). After another 24h, target proteins in the whole cell lysates were examined by immunoblotting. (L)D a x xl o s e si t s
capacity to downregulate p53 when PA28g is absent. MEF cells (PA28g
þ/þ or PA28g
 / ) were transfected with a plasmid to overexpress Daxx (3mg) or a
control plasmid (3mg). Whole cell lysates were collected for the examination of target proteins 24h later. (M)P A 2 8 g is not involved in the downregulation of
p53 by YY1. HCT116 cells pretreated with the PA28gsiRNA pool or control siRNA pool (1.25nM for each duplex) for 24h were transfected with a plasmid to
overexpress YY1 (3mg) or a control plasmid (3mg). After another 24h, whole cell lysates were collected for examination of target proteins.
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PA28g knockdown did not result in apparent changes in the
levels of Numb or MDM4 (two other substrates of MDM2) in
HCT116 cells, although upregulation of p53 was observed
(Figure 5G).
PA28c regulates apoptosis through p53
To demonstrate that PA28g regulates apoptosis through
modulation of p53, we compared survival and apoptosis of
cells treated with a PA28g siRNA pool or a control siRNA
pool. The tested cancer cell lines included: A549 (wt p53); a
pair of MCF-7 cell lines (one with wt p53 (p53
þ/þ) and one
nullizygous for p53 (p53
 / ) by stable knockdown of p53
by siRNA; Li et al, 2005); a pair of HCT116 cell lines (one with
wt p53 (p53
þ/þ) and one nullizygous for p53 (p53
 / )b y
deletion of p53 through homologous recombination); and
PC3 cells (p53 null). Knockdown of PA28g resulted in a
reduction in the survival of A549, MCF-7 (p53
þ/þ), and
HCT116 (p53
þ/þ) cells (Figure 6A and Supplementary
Figure S7) and in higher numbers of apoptotic cells
(Figure 6B and Supplementary Figure S7). In contrast, there
were no effects on the survival or apoptosis of MCF-7 p53
 / ,
HCT116 p53
 / , or PC3 (p53
null) cells (Figures 6A and B and
Supplementary Figure S7).
Similarly, g-irradiation-induced accumulation of p53
was reduced by overexpression of PA28g in MCF-7 cells
(Figure 6C), and overexpressed PA28g stabilized the
MDM2–p53 interaction in the presence of g-irradiation
(Figure 6D). The extent of apoptosis in MCF-7 cells with
overexpressed PA28g was also lower than in control cells
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HCT116 cells inhibited the radiosensitizing effect of PA28g
siRNA on cells (Figure 6F).
MDM2 is considered a target for human cancer therapy
(Bond et al, 2004; Zhang et al, 2005; Poyurovsky and Prives,
2006). Several experimental therapeutic molecules, including
a speciﬁc anti-MDM2 antisense oligonucleotide (AS), have
been developed (Zhang et al, 2003, 2005). However, the
response of p53 to inhibition of MDM2 by AS varies in
different cell lines. These differences might reﬂect variations
in the basal levels of endogenous PA28g. Analysis of the basal
expression of PA28g in six cancer cell lines with wild-type p53
IB: MDM2
IB: p53 
IB: PA28  γ
1
0
%
 
i
n
p
u
t
MDM2-T7 
IB: T7
IB: GFP
p53-HA
PA28γ-GFP 
PA28γ-GFP 
PA28γ-GFP 
 
IB: HA
p53-HA
IB: GFP 
10% input IP: GFP 
10% input IP: GFP
10% input IP: T7
10% input IP: HA
IP IP IP
IgG IgG MDM2
1
0
%
 
i
n
p
u
t
IB: PA28  γ  
IB: MDM2
IB: PA28γ  
IB: p53 
+
+
+
+
+
+ –
+
–
–
+
–
+
+
+
+
+
+ –
+
–
–
+
–
+
+
+
+
+
+ –
+
–
–
+
–
MDM2-T7 
PA28γ-GFP 
+
+
+
+
+
+ –
+
–
–
+
–
1
0
%
 
i
n
p
u
t
G
S
T
 
G
S
T
-
M
D
M
2
1
0
%
 
i
n
p
u
t
G
S
T
 
G
S
T
-
P
A
2
8
γ
1
0
%
 
i
n
p
u
t
G
S
T
 
G
S
T
-
p
5
3
 
1
0
%
 
I
n
p
u
t
G
S
T
 
G
S
T
-
P
A
2
8
 
1
0
%
 
i
n
p
u
t
IgG p53
U2OS A549 In vitro
pull down
GST-MDM2 
p53 
PA28  γ
pEF-PA28γ   siRNA pool
p53 
MDM2
p53 
MDM2
PA28γ  
β-Actin
β-Actin
IP: p53 
10% input    
–   +  ++ Control PA28γ 
p53 bound by
GST-MDM2 
p53 input
+ + 
+ + 
– + 
MEF
p53 
MDM2
MDM2
p53 
PA28γ
PA28γ  γ –/– PA28γ  γ +/+
 
IP: p53 
10% input
Elution volume (ml):  0     10     20   30   40
1
0
%
 
i
n
p
u
t
GFP + p53-HA + MDM2-T7
Elution volume (ml) 
12 18 21.5 22.5 23 23.5 24 24.5   25  25.5 26 29  29.5  30  30.5  31  31.5
12 18 21.5 22.5 23 23.5 24 24.5   25  25.5 26 29  29.5   30  30.5  31  31.5
1
0
%
 
i
n
p
u
t
GFP-PA28  γ   + p53-HA + MDM2-T7
    Elution volume (ml) 
T7
HA
GFP
T7
HA
GFP
Elution volume (ml):   0     10     20    30   40 
24.2 ml  
GFP-PA28γ   + p53-HA + MDM2-T7
GFP + p53-HA + MDM2-T7  ab c d e f g
ab c d ef g
a: 669 kDa
b: 440 kDa 
c: 232 kDa
d: 67 kDa 
e: 43 kDa 
f: 25 kda  
g: 13.7 kDa 
a: 669 kDa
b: 440 kDa 
c: 232 kDa
d: 67 kDa 
e: 43 kDa 
f: 25 kda  
g: 13.7 kDa 
 669 kDa 440 kDa 232 kDa 67 kDa
 669 kDa 440 kDa 232 kDa 67 kDa
PA28γ
PA28c modulates MDM2–p53 interaction
Z Zhang and R Zhang
The EMBO Journal VOL 27 | NO 6 | 2008 &2008 European Molecular Biology Organization 858demonstrated that U2OS cells had the lowest level of PA28g
(Figure 6G). Interestingly, MDM2 inhibition in U2OS cells did
not result in any appreciable enhancement of the level of
p53 (Figure 6H). In contrast, p53 accumulated following
inhibition of MDM2 in the other cells (Figure 6H).
To examine whether downregulation of PA28g enhances
the effects of MDM2 inhibition in cancer cells with a high
level of PA28g, HCT116 and A549 cells were exposed to a
combination of Nutlin-3 (3mM) and PA28g siRNA. The
combination led to a synergistic upregulation of p53
(Figure 6I), inhibited survival, and enhanced apoptosis
(Figure 6J). This suggests a new strategy for sensitizing
human cancers to MDM2 inhibitors.
Discussion
The role of MDM2 in regulating p53 is supported by trans-
genic animal studies (Jones et al, 1995; Montes de Oca Luna
et al, 1995). Several regulators of the MDM2–p53 interaction
have been identiﬁed, including p14
Arf (Pomerantz et al, 1998;
Zhang et al, 1998a), YY1 (Sui et al, 2004), MDMX (Francoz
et al, 2006), gankyrin (Higashitsuji et al, 2005), L11 (Lohrum
et al, 2003), and Daxx (Tang et al, 2006). This large number
of regulatory molecules indicates the complexity of the
MDM2–p53 interaction. The pattern of p53 degradation
depends on the cellular level of MDM2 (Li et al, 2003).
Further, in different human cancer cell lines, the extent of
p53 accumulation varies even when a similar level of MDM2
inhibition has been achieved (Zhang et al, 2005). The identi-
ﬁcation of PA28g as a cofactor for the degradation of p53
suggests a new model for p53 degradation, in which PA28g
regulates the MDM2–p53 interaction and MDM2-dependent
degradation. Without PA28g, MDM2 induces p53 monoubi-
quitination and nuclear export; subsequent polyubiquitina-
tion is catalysed by cytoplasmic factors. When PA28g is
present, p53 is efﬁciently polyubiquitinated by low levels
of MDM2 within the nucleus, and the p53 level remains
under stringent control by MDM2. This could provide
advantages to cells in that it would circumvent the need
for elevated levels of MDM2 and the need for nucleus-to-
cytoplasm transport.
Recent studies have shown that MDM2 can form polymers
to increase the local concentrations of components of the
ubiquitination reaction and provide a binding surface for
multiple E2s (Poyurovsky et al, 2007). We have observed
by FPLC analysis that in lysates of GFP-PA28g-transfected
cells, a portion of MDM2 appeared with GFP-PA28g and p53
in the fractions with molecular weights higher than 669kDa
(Figure 4G, right panel). It is possible that polymerized PA28g
mediates the interactions not only between p53 and mono-
meric MDM2 (appearing in fractions B560kDa) but also
between p53 and polymeric MDM2. This high-order structure
would allow for efﬁcient MDM2-dependent polyubiquitina-
tion of p53. The protein complex may also provide a scaffold
to orient the substrates, in addition to increasing the local
concentrations of the components, especially when the
amounts of cellular E2 are low.
MDM2 is being considered as a target for human cancer
therapy. We have provided evidence that PA28g has an
integral function in regulating the MDM2–p53 interaction
by facilitating the interaction of the two proteins. This
observation may have clinical implications. In designing
future trials of agents targeting MDM2, screening for the
expression of PA28g in cancer patients should be taken into
account.
Another interesting observation is that the change in
MDM2 expression in different cells is not the same after
PA28g overexpression. MDM2 is a target of p53, and PA28g
is a negative regulator of p53. Therefore, overexpression of
PA28g in cells may result in a decrease in the level of MDM2.
This may occur through the inhibition of the transactivation
activity of p53 by PA28g. Although this seems to be the case
in A549 cells, at the current stage we cannot completely rule
out the possibility that PA28g may directly regulate MDM2 or
may regulate the oncoprotein through other pathways. These
mechanisms may be cell-type dependent. Future studies
investigating the possible regulatory function of PA28g on
MDM2 expression either in the presence or absence of p53
are warranted.
This study reveals a previously unrecognized mechanism
underlying the effects of PA28g on apoptosis and cell cycle
regulation. Although one PA28g substrate, SRC-3/AIB1, had
been identiﬁed previously (Li et al, 2006), its pro-growth
Figure 4 PA28g protein interacts with both MDM2 and p53 proteins and promotes the MDM2–p53 interaction. (A) Endogenous PA28g, MDM2,
and p53 interact in intact cells. Lysates of MCF-7 cells were immunoprecipitated by PA28g (Invitrogen) (left panel), MDM2 (N-20) (middle
panel), or p53 (FL393) (right panel), and target proteins in the immunocomplexes were separated by SDS–PAGE and detected by antibodies
against MDM2 (SMP14), p53 (DO-1), or PA28g (BD Biosciences). (B) PA28g interacts with MDM2 and p53 in vitro. GST-MDM2 (upper panel,
left) or GST-PA28g (lower panel, left) was incubated with in vitro-translated PA28g or MDM2. The complex was pulled down by GST beads, and
the target proteins were detected by PA28g or MDM2 antibody (SMP14). GST-p53 (upper panel, right) or GST-PA28g (lower panel, right) was
incubated with in vitro-translated PA28g or p53. The complex was pulled down by GST beads, and the target proteins were detected by PA28g
or p53 antibody (DO-1). (C) Exogenous MDM2, p53, and PA28g interact in COS7 cells. COS7 cells were transfected with p53-HA or PA28g-GFP,
or both (upper panel), and cell lysates were immunoprecipitated by GFPor HA antibody. The binding between p53 and PA28g was examined by
immunoblotting with HA or GFP antibody. In a separate experiment, COS7 cells were transfected with MDM2-T7 or PA28g-GFP, or both (lower
panel), then cell lysates were immunoprecipitated by GFP or T7 antibody. The binding between MDM2 and PA28g was examined by
immunoblotting with T7 or GFP antibody. (D–F) PA28g promotes the binding between endogenous MDM2 and p53 in cells and in vitro. (D)
The interaction between MDM2 and p53 in U2OS cells with overexpression of PA28g (0, 3, and 5mg) (left panel), or in A549 cells with PA28g
knockdown by PA28g siRNA pool (1.25nM for each duplex) (right panel), was examined by immunoprecipitation with p53 antibody (FL393)
followed by immunoblotting with MDM2 antibody (SMP14). (E) GST-MDM2 was incubated with in vitro-translated p53 in the presence or
absence of PA28g at 41C for 4h. p53 bound by GST-MDM2 was pulled down by GST beads, eluted by SDS sample buffer at 1001C for 10min, and
detected by immunoblotting with p53 antibody, DO-1. (F) Cell lysates of low passage MEF were immunoprecipitated with p53 antibody FL393,
and the immunoprecipitates were separated on SDS–PAGE. Target proteins were detected by immunoblotting with speciﬁc antibodies. (G) The
polymer of PA28g mediates the interaction with MDM2 and p53. COS7 cells were transfected with plasmids overexpressing GFP or GFP-PA28g
with MDM2-T7 and p53-HA (5mg for each plasmid per 100mm dish). Cell lysates were collected and subjected to gel ﬁltration using the
Superose 6/Superdex 200 system 24h later. The absorbance proﬁles are shown in the left panel. Eluted fractions were subjected to 10%
SDS–PAGE, and target proteins were detected by immunoblotting (right panel).
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Figure 5 PA28g speciﬁcally downregulates p53. (A–C) PA28g mutants lacking the capacity to activate the proteasome still promote p53
degradation in cells, whereas a mutant lacking the insert region is incapable of facilitating p53 degradation. U2OS cells were transfected with
GFP-PA28g, mutants P245Y, G150S, N151Y, D76–103, or GFP (4mg for each plasmid). The stability of endogenous p53 was determined by
immunoblotting (left panel). The relative densitometry data at each time point are expressed as a percentage of the density of p53 at time 0,
normalized to the corresponding b-actin level. The average of the relative densitometry data in the three independent experiments are shown in
the right panel. *Po 0.05. (B) U2OS cells were transfected with ubiquitin (2mg per 60mm dish) with either GFP, GFP-PA28g, or GFP-PA28g-
D76–103 (4mg per 60mm dish) for 28h, followed by the exposure to proteasome inhibitor MG132 (15mM) for 4h. Cell lysates were
immunoprecipitated with p53 antibody FL393. The immunoprecipitates were separated on 10% SDS–PAGE and immunoblotted with
polyubiquitin chain antibody, FK1. (C) His-p53 (6ng) was incubated with His-MDM2 (6ng) and GST-PA28g (30ng), or GST-PA28g-D76–103
(30ng) for 3h in the presence of E1 (10ng), E2 (40ng), and ubiquitin (5mg). Ubiquitinated p53 was detected by immunoblotting with the p53
antibody, DO-1. A series of plasmids expressing mutants of PA28g were transfected with MDM2-T7 (D) or p53-HA (E) into COS7 cells.
Sequential assays of immunoprecipitation with GFPantibody and immunoblotting with T7 (D) or HA (E) antibody were employed to determine
the region essential for the binding of PA28g to MDM2 or p53. (F) A summary of the capacities of the PA28g mutants to bind to MDM2 and p53.
(G) HCT116 cells were treated with a control siRNA duplex or a PA28g siRNA duplex (10nM, 48h). Target proteins were detected by
immunoblotting.
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antiproliferative phenotypes following PA28g knockdown.
Recently, p21
Waf1 was also demonstrated to be a substrate
of PA28g (Chen et al, 2007; Li et al, 2007). Although the
cell cycle arrest phenotype of PA28g knockdown could be
explained by its effects on p21
Waf1, the mechanisms responsible
for its induction of apoptosis were not clear. We have
identiﬁed an interaction among PA28g, MDM2, and p53,
which have established activities in apoptosis and cell pro-
liferation. This interaction could provide the missing link
between PA28g and apoptosis.
In support of this theory, PA28g
 /  mice, although viable,
have a phenotype similar to transgenic mice with hypo-
morphic MDM2. We also observed that PA28g has a negative
regulatory function in the level of p53 in both MEF cells and
normal breast epithelial MCF10A cells. It is possible that the
viability of PA28g
 /  mice may depend on the presence of
other p53-regulatory molecules when PA28g is knocked
down. For example, we have observed that YY1 is still
capable of downregulating p53 in the presence of PA28g
knockdown (Figure 3M). Recent efforts have identiﬁed sev-
eral cellular factors that selectively regulate the transactiva-
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These molecules may also regulate the activities of p53 in the
absence of PA28g.
MDM2 knockout results in lethality early in development
in mice (Jones et al, 1995; Montes de Oca Luna et al, 1995).
This may result from a p53-mediated hypoxic response due to
the lack of regulation by MDM2. It is possible that the
regulation of MDM2–p53 by PA28g may not be involved in
this stage of early development, or that other cofactors have a
more important function at this stage, which could explain
the viability of PA28g
 /  mice. Nonetheless, in support of the
effects of PA28g on p53 regulation, PA28g
 /  mice, although
viable, have reduced adult body mass, growth retardation,
and demonstrate spontaneous apoptosis and G1 arrest in
embryonic ﬁbroblasts.
In conclusion, the present study (a) identiﬁes a novel
factor involved in the regulation of the MDM2–p53 interac-
tion; (b) indicates that a previously undeﬁned partner of
MDM2 is required for the degradation of p53 protein; (c)
suggests a novel mechanism by which PA28g regulates
apoptosis and cell proliferation; (d) demonstrates that
PA28g mediates the degradation of intact proteins in addition
to peptides; and (e) provides a possible new target for human
cancer therapy.
Materials and methods
Cells
LNCaP, A549, MCF-7, and PC3 cells were purchased from the ATCC.
U2OS, and HCT116 p53
þ/þ and HCT116 p53
 /  cells were
provided by Dr X Chen (UC Davis) and Dr B Vogelstein (Johns
Hopkins), respectively. MCF-7 cells with stable p53 knockdown
have been described previously (Li et al, 2005). All cells were
cultured under standard conditions described by the ATCC.
PA28g
þ/þ and PA28g
 /  MEFs and immortalized MEF cells
(3 passages after immortalization, B20 passages from initial
culture) were kindly provided by Dr L Barton (Austin College).
The temperature-sensitive Balb/c 3T3 cell line, ts20b, was a gift
from Dr O Harvey (UMDNJ-New Jersey Medical School).
Antibodies
Antibodies were obtained from Afﬁnity (proteasome a/b subunit,
S7/Rpt1, and PA28b), BD Biosciences (mouse PA28g), Calbiochem
(p53 DO-1, T7, and human p21
Waf1 Ab-1), Cell Signaling (Puma and
Numb), Covance (HA.11), Invitrogen (rabbit polyclonal PA28g),
Santa Cruz (p53 FL393, 14-3-3s, MDM4, MDM2 SMP14, and MDM2
N-20), and Sigma (Flag M2 and GFP-N-terminal).
Plasmids, oligonucleotides, and reagents
Various plasmids were kind gifts from other investigators, including
Flag-tagged pcDNA3-PA28b and pEF-PA28g (Dr Y Matsuura, Osaka
University, Japan), pcDNA3-p53-HA, pcGT-T7-MDM2, p21
Waf1
luciferase reporter, and pBabe-U6-p53 (Dr X Chen, UC Davis),
pcMV-MDM2 and pcMV-p53 (Dr J Chen, Mofﬁtt Cancer Center),
HA-Ub and YY1-HA (Dr Y Shi, Harvard), and Daxx-HA (Dr X Yang,
U Penn). The GFP-C1-PA28g, PGEX-2T-PA28g and pcDNA3-PA28g
vectors were generated by proof-reading PCR, and mutants GFP-C1-
PA28g-P245Y, -G150S and -N151Y were produced using the
QuikChange
s site-directed mutagenesis kit (Stratagene) and
veriﬁed by sequencing. MDM2 antisense and mismatch oligonu-
cleotides have been described previously (Zhang et al, 2003, 2005).
Nutlin-3, cycloheximide (CHX), and MG132 were purchased from
Sigma-Aldrich. E1, E2 (UbcH5b), and Myc-Ubiquitin for in vitro
ubiquitination assays were purchased from Boston Biochem, and
20S and 26S proteasomes were purchased from Biomol.
Immunoprecipitation and immunoblotting
Cells were lysed in NP-40 buffer, then lysates were immunopreci-
pitated with speciﬁc antibodies and examined by immunoblotting.
The Supplementary data can be consulted for additional details.
Generation of GST fusion proteins and pull-down assays
Direct physical binding in vitro between the MDM2 protein and
PA28g, or between p53 and PA28g, was assessed using GST fusion
proteins. The bound proteins were captured by glutathione-agarose
beads and resolved on SDS–PAGE. Details are available in the
Supplementary data section.
Puriﬁcation of His-tagged recombinant proteins and in vitro
ubiquitination assay
MDM2 and p53 fusion proteins were generated in Escherichia coli,
then puriﬁed on Ni-NTA Superﬂow Columns. We utilized a
previously described protocol to evaluate ubiquitination (Li et al,
2003). Ubiquitinated p53 was detected by immunoblotting with the
DO-1 p53 antibody. For more details about these experiments,
please see the Supplementary data.
In vitro proteasome degradation assay
A modiﬁcation of a published protocol was used to evaluate
proteasomal degradation of p53 and p21 (Dai et al, 2006; see
Supplementary data). An aliquot of the reaction was analysed by
immunoblotting.
Figure 6 PA28g regulates apoptosis through p53. (A, B) PA28g knockdown results in p53-mediated cell killing. (A) A549, MCF-7 p53
þ/þ, and
MCF-7 p53
 /  cells were treated with a control siRNA pool (5nM of each duplex) or a PA28g siRNA pool (1.25, 2.5, or 5nM of each duplex),
and cell viability was determined by MTTassay. (B) A549, MCF-7 p53
þ/þ, and MCF-7 p53
 /  cells were treated with a PA28g siRNA pool or
control siRNA pool as above, and apoptotic cells were detected by ﬂow cytometry. The relative percentages of surviving cells and apoptotic
indices are presented as the means7s.d. of three independent samples. (C–F) PA28g inhibits p53 accumulation and apoptosis following
g-irradiation (IR). (C) MCF-7 cells were transfected with PA28g (3mg) or control vector (3mg), 24h later cells were exposed to g-irradiation (8Gy).
Target proteins in whole cell lysates collected at different time points after irradiation were detected by immunoblotting. (D) A549 cells were
transfected with a plasmid overexpressing PA28g (3mg) or the control vector (3mg). Cells were exposed to g-irradiation (8Gy) 24h later. After
different time periods, cell lysates were immunoprecipitated by p53 antibody FL393, and the immunoprecipitates were separated on 10% SDS–
PAGE. Target proteins were detected by immunoblotting. (E) MCF-7 cells with transiently overexpressed GFP-PA28g (3mg) or GFP (3mg) were
exposed to g-irradiation. After 8h, cells were collected and ﬁxed in 70% ethanol at 41C overnight. After staining with PI, GFP-positive cell
populations were counted by ﬂow cytometry to determine DNA content, and the sub-G1 populations were selected to represent the apoptotic
cells. Relative apoptotic indices are presented as the means7s.d. of two independent samples. (F) HCT116 p53
þ/þ and HCT116 p53
 /  cells
were pretreated with the PA28g siRNA or control siRNA pool (0.625nM for each siRNA) (24h) or were exposed to g-irradiation (8Gy). After
another 24h, cell viability was determined by MTT assay. The relative percentages of surviving cells are presented as means7s.d. of three
independent samples. (G, H) The enhanced levels of p53 in different cancer cell lines upon MDM2 inhibition is related to the level of
endogenous PA28g. Cancer cells were examined for basal PA28g protein (G), then treated with MDM2 AS (50 and 150nM) or ASM (150nM).
After 24h, target proteins were detected by immunoblotting (H). (I, J) PA28g knockdown in human cancer cells with high levels of endogenous
PA28g sensitizes them to Nutlin-3. (I) HCT116 and A549 cells were transfected with a control or PA28g siRNA pool (1.25nM for each duplex).
3h after transfection, 3mM Nutlin-3 or the solvent, DMSO, was added to the culture media, and 24h after transfection, target proteins were
detected by immunoblotting. (J) A549 cells were treated as described in (G), then cell viability was determined by MTTassay, and apoptotic
cells were detected by ﬂow cytometry. The relative percentages of surviving cells and apoptotic indices are presented as the means7s.d. of
three independent samples. MTTand apoptosis assays were performed at least twice, and similar results were observed. *Po0.05;
wPo0.0001.
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The PA28g, p53, and control siRNA pools, individual siRNA
duplexes targeting PA28g or PA28b, the control siRNA duplex
randomly selected from the siRNA pool, and the transfection
reagent DharmaFECTTM 1 were purchased from Dharmacon. siRNA
transfection was performed according to the manufacturer’s
protocol. For immunoblotting assays using the siRNA pool, cells
were incubated with 1.25nM of each siRNA for 24h; for MTT and
apoptosis assays, 0.625, 1.25, 2.5, or 5nM of each siRNA was
incubated with cells for 48h.
Analytical gel ﬁltration chromatography
Analysis of protein proﬁles of lysates from COS7 cells transfected
with MDM2-T7, p53-HA, GFP, or GFP-PA28g by the FPLC method
was accomplished following a previously described protocol
(Garber et al, 2000). Detailed information is provided in the
Supplementary data.
RT–PCR
The extraction of total RNA, reverse transcription, and PCR were
performed according to the procedures described previously (Zhang
et al, 2003). Details are available in the Supplementary data.
Luciferase assay
Cells were co-transfected with full-length p21
Waf1 promoter vectors
with the Renilla luciferase reporter (as an internal control;
Promega) for 24h. The luciferase activity of the p21
Waf1
promoter reporter was determined using the Dual-Luciferase
Reporter Assay System (Promega) according to the provided
protocol, and normalized to the corresponding Renilla luciferase
reporter activity.
Cell survival, apoptosis, and cell cycle distribution assays
MTTs assay to measure the cell viability, and apoptosis and cell
cycle distribution assays were accomplished according to methods
described previously (Li et al, 2005).
c-Irradiation
Cells were placed in a
60Co Picker unit irradiator (1.56Gy/min) and
exposed to 8Gy g-irradiation.
Statistical analysis
The means of relative densitometry of p53 bands, survival indices,
and apoptotic indices between two treatment groups were analysed
using the two-tailed paired t-test. The signiﬁcance of the variances
of means of indices in multiple treatment groups was initially
analysed by ANOVA. If positive (Po0.05), the means between
the control and each treatment group were analysed using the two-
tailed paired t-test.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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